TAIDOC TECHNOLOGY CORP (4736) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of TAIDOC TECHNOLOGY CORP stock TWD 128, price TWD 126, upside +1.4%, quality 70 out of 100. Rating: fairly valued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 97.99 TWD – 187.07 TWD · fair‑value band 88.89 TWD – 176.92 TWD · the 126.00 TWD price screens below the 127.80 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow TAIDOC TECHNOLOGY in your weekly email
Every Wednesday you see whether TAIDOC TECHNOLOGY is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
TaiDoc Technology Corporation manufactures and markets medical devices in Taiwan and internationally.
Show moreShow less
The company offers In vitro diagnostics products, including multiple parameter monitoring systems, point of care testing devices, and lancet and lancing devices; vet health care products comprise blood glucose and calcium meters, and blood ketone meters; and medical devices, such as nebulizers, thermometers, blood pressure monitors, vital sign monitors, and pulse oximeters.
It also provides telehealth remote monitoring devices and smartphone applications; and Covid-19 antigen rapid test kits. In addition, the company offers services for regulatory professionals, as well as in the areas of clinical suggestions, engineering resources, and manufacturing systems.
Further, the company provides various applications, including MyLink, ProCheck, Healthy Check, Healthy Check PRO, PCLink, and USB adapter driver. TaiDoc Technology Corporation was founded in 1998 and is headquartered in New Taipei City, Taiwan.
Stock analysis
TAIDOC TECHNOLOGY CORP (4736) currently trades at 126.00 TWD, while our model-based Fair Value estimate is 127.80 TWD, so the stock looks roughly fairly valued today (gap 1.4%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 250.51 TWD per share, and 14 of the 25 models we run sit above the 126.00 TWD price.
Bear case: the Asset-Based group reads lowest at 44.16 TWD, and 11 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: 88.89 TWD (bear) to 176.92 TWD (bull), the price of 126.00 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
TAIDOC TECHNOLOGY CORP reported revenue of 4.2B TWD in FY2025 versus 6.5B TWD in FY2021, a compound −10.3%/yr. Reported net income was 1.4B TWD in FY2025, compounding −7.6%/yr from FY2021.
Key figures
Market cap 13.2B TWD (≈ $401M) Small · P/E ratio 5.2 · P/S ratio 3.11 · EPS (TTM) 24.33 TWD · Dividend yield 3.6% · Net margin 60.7% · Return on equity 25.7% · Return on assets (EBIT) 15.0% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 73 out of 100 (low confidence).
What moves the price
The share trades about 6% below its 52-week high and 20% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 1%, 4736 screens cheaper than that median.
Fair Value models
Bear88.89 TWDFair Value 127.80 TWDBull176.92 TWD
Price 126.00 TWD · Upside +1.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (19.79 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−9.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.6%
Start year 2020 (pandemic). Over 10 years: +4.8% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+1.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.8%
Dividend (yield on the price)3.6%
Per share before 2026divided by the spin-off factor 1.1014
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−1.8% vs 10.6%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.32% → 23%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+3.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +2.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside+1.4% · Above median
Profitability
Return on equity (12 months)25.7% · Top 25%
Return on assets11.3% · Top 25%
Net margin (12 months)60.7% · Top 25%
Operating margin (12 months)13.5% · Above median
Growth and dividend
Revenue growth (quarter YoY)−6.6% · Bottom 25%
Dividend yield (12 months)3.6% · Top 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)5.2× · Cheapest 25%
P/B1.34× · Cheaper than median
P/S (12 months)3.11× · Pricier than median
Price / free cash flow (fiscal year)21.8× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is TAIDOC TECHNOLOGY CORP (4736) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 127.80 TWD versus a price of 126.00 TWD, about +1% upside (fairly valued).
What is the fair value of 4736?
Our model-based fair value for TAIDOC TECHNOLOGY CORP is 127.80 TWD (as of Nov 3, 2026), built from audited fundamentals. The current price: 126.00 TWD.
What is the quality score of 4736?
TAIDOC TECHNOLOGY CORP has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TAIDOC TECHNOLOGY CORP (4736)?
Our model-based price target is the fair value of 127.80 TWD (as of Nov 3, 2026) from 25 valuation models. Cautious scenario 88.89 TWD, optimistic scenario 176.92 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the TAIDOC TECHNOLOGY CORP stock forecast for 2026?
Our models put fair value at 127.80 TWD, about +1% upside versus a price of 126.00 TWD (fairly valued). Cautious scenario 88.89 TWD, optimistic scenario 176.92 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of TAIDOC TECHNOLOGY CORP (4736)?
TAIDOC TECHNOLOGY CORP reported trailing-twelve-month revenue of about 4.2B TWD (latest available figure, as of Nov 3, 2026).
Does TAIDOC TECHNOLOGY CORP pay a dividend?
TAIDOC TECHNOLOGY CORP currently shows a dividend yield of 3.60% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of TAIDOC TECHNOLOGY CORP (4736) and when is the ex-dividend date?
TAIDOC TECHNOLOGY CORP pays a dividend of 4.54 TWD per share a year, a dividend yield of 3.6%. The last ex-dividend date was Aug 27, 2026. A dividend has been paid every year since at least 2011. The payout ratio is 18.7% of earnings. Free cash flow covers the dividend 1.28 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into TAIDOC TECHNOLOGY CORP (4736)?
For today's price to be fair in a discounted-cash-flow model, TAIDOC TECHNOLOGY CORP would have to grow free cash flow by +3.6 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -6.6 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 4736 use?
Our models discount TAIDOC TECHNOLOGY CORP at 10.3 %: a base by market capitalisation (small), damped by beta 0.22, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For TAIDOC TECHNOLOGY CORP that is +3.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has TAIDOC TECHNOLOGY CORP (4736) delivered so far?
Over the past 5 years revenue at TAIDOC TECHNOLOGY CORP grew -6.6 % a year. The price currently implies free-cash-flow growth of +3.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of TAIDOC TECHNOLOGY CORP (4736) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into TAIDOC TECHNOLOGY CORP (+3.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of TAIDOC TECHNOLOGY CORP (4736)?
The free-cash-flow yield on the price is 4.97 %: that much free cash flow TAIDOC TECHNOLOGY CORP produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of TAIDOC TECHNOLOGY CORP (4736)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TAIDOC TECHNOLOGY CORP it is 127.80 TWD per share (as of Nov 3, 2026), against a price of 126.00 TWD. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is TAIDOC TECHNOLOGY CORP stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 4736 trades below its calculated fair value: price 126.00 TWD, fair value 127.80 TWD, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4736?
No. The price is what the market pays today (126.00 TWD); the fair value is what the company's own numbers justify (127.80 TWD). For TAIDOC TECHNOLOGY CORP the two are 1.80 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is TAIDOC TECHNOLOGY CORP worth?
The market values TAIDOC TECHNOLOGY CORP at about 13.2B TWD (market capitalisation, as of Nov 3, 2026). Per share that is 126.00 TWD; our models calculate a fair value of 127.80 TWD per share.
What do the bullish and bearish scenarios say about 4736?
Our models span a range for TAIDOC TECHNOLOGY CORP: cautious scenario 88.89 TWD, base 127.80 TWD, optimistic 176.92 TWD per share (as of Nov 3, 2026, price 126.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4736?
TAIDOC TECHNOLOGY CORP trades at a price-to-earnings ratio of 5.2 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 127.80 TWD is built from several models across several years. Other multiples: P/B 1.3, P/S 3.1, EV/EBITDA 12.7.
How solid is the balance sheet of TAIDOC TECHNOLOGY CORP (4736)?
Balance-sheet figures for TAIDOC TECHNOLOGY CORP (as of Nov 3, 2026): return on equity 25.7%, debt of 0.02 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is 4736 from its 52-week high?
TAIDOC TECHNOLOGY CORP trades at 126.00 TWD, about 6% below its 52-week high of 134.50 TWD and 20% above the low of 104.57 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 127.80 TWD is for.
Which stocks are comparable to TAIDOC TECHNOLOGY CORP?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TAIDOC TECHNOLOGY CORP stock attractive at the current price?
The data as of Nov 3, 2026: price 126.00 TWD, calculated fair value 127.80 TWD (+1%), Quality Score 70/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4736 calculated?
We run TAIDOC TECHNOLOGY CORP through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 127.80 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. TAIDOC TECHNOLOGY CORP currently trades 1% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TAIDOC TECHNOLOGY CORP (4736)?
The closing price on Nov 6, 2026 was 126.00 TWD. Our model-based fair value is 127.80 TWD, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TAIDOC TECHNOLOGY CORP right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (88.89 TWD to 176.92 TWD) leaves room in how you read the outcome.
Where does the earnings growth of TAIDOC TECHNOLOGY CORP (4736) come from?
Earnings per share at TAIDOC TECHNOLOGY CORP grew +9.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.7 %, EBIT margin +0.6 %, tax rate −0.2 %, residual (interest, one-offs) +5.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of TAIDOC TECHNOLOGY CORP
How large is the market capitalisation of TAIDOC TECHNOLOGY CORP (4736)?
The market capitalisation of TAIDOC TECHNOLOGY CORP is 13.2B TWD (≈ $401M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TAIDOC TECHNOLOGY CORP (4736)?
The price-to-sales ratio of TAIDOC TECHNOLOGY CORP is 3.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of TAIDOC TECHNOLOGY CORP (4736)?
Earnings per share at TAIDOC TECHNOLOGY CORP are 24.33 TWD (price ÷ EPS = P/E 5.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of TAIDOC TECHNOLOGY CORP (4736)?
The dividend yield of TAIDOC TECHNOLOGY CORP is 3.6% (payout 18.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of TAIDOC TECHNOLOGY CORP (4736)?
The net margin of TAIDOC TECHNOLOGY CORP is 60.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TAIDOC TECHNOLOGY CORP (4736)?
The return on equity (ROE) of TAIDOC TECHNOLOGY CORP is 25.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TAIDOC TECHNOLOGY CORP (4736)?
On an EBIT basis the return on assets of TAIDOC TECHNOLOGY CORP is 15.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TAIDOC TECHNOLOGY CORP (4736)?
The operating margin of TAIDOC TECHNOLOGY CORP is 13.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TAIDOC TECHNOLOGY CORP (4736)?
Revenue at TAIDOC TECHNOLOGY CORP is growing −6.6% versus a year earlier (3y avg −24.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at TAIDOC TECHNOLOGY CORP (4736)?
Earnings per share at TAIDOC TECHNOLOGY CORP are growing +179% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does TAIDOC TECHNOLOGY CORP (4736) hold?
TAIDOC TECHNOLOGY CORP holds more cash than debt, 910M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch TAIDOC TECHNOLOGY CORP in the live analysis
One click puts TAIDOC TECHNOLOGY CORP on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 3, 2026